Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Treatment of hairy cell leukemia with 2chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience by Punit Chadha, Alfred W. Rademaker, Prateek Mendiratta, Benjamin Kim, Darren M. Evanchuk, David Hakimian, LoAnn C. Peterson, and Martin S. Tallman Blood Volume 106(1):241-246 July 1, 2005 ©2005 by American Society of Hematology Diagram of response and relapse to cycle no. 1 and response to cycle no. 2 in patients with HCL treated with 2-CdA. * One of the 25 patients was treated with rituximab (CR), and one of 25 was retreated with 2′-DCF (CR). † One (4%) of 23 patients' responses ... Punit Chadha et al. Blood 2005;106:241-246 ©2005 by American Society of Hematology PFS for all 86 patients with HCL. Dotted lines represent 95% confidence limits. Punit Chadha et al. Blood 2005;106:241-246 ©2005 by American Society of Hematology PFS for previously treated and previously untreated patients with HCL. Tx indicates treated. Punit Chadha et al. Blood 2005;106:241-246 ©2005 by American Society of Hematology PFS for patients with HCL achieving CR with one cycle of 2-CdA. Punit Chadha et al. Blood 2005;106:241-246 ©2005 by American Society of Hematology OS for all 86 patients with HCL. Dotted lines represent 95% confidence limits. Punit Chadha et al. Blood 2005;106:241-246 ©2005 by American Society of Hematology OS for previously treated and previously untreated patients with HCL. Tx indicates treated. Punit Chadha et al. Blood 2005;106:241-246 ©2005 by American Society of Hematology OS for relapsed patients with HCL. Dotted lines represent 95% confidence limits. Punit Chadha et al. Blood 2005;106:241-246 ©2005 by American Society of Hematology OS for patients with HCL achieving CR with one cycle of 2-CdA. Punit Chadha et al. Blood 2005;106:241-246 ©2005 by American Society of Hematology